The pharmaceutical sector performed strongly, with many stocks up and down, and one stock won four consecutive boards!

【Pharmaceutical Network Pharmaceutical Stock Market】On October 18, the pharmaceutical sector performed strongly, with Watson Pharmaceutical, Jingjing Pharmaceutical, Lifang Pharmaceutical, Onlikang, Panlong Pharmaceutical, Jingxin Pharmaceutical, Zixin Pharmaceutical and other stocks up and down, among which microelectrophysiology walked out of the triple board, and Shuangcheng Pharmaceutical won the fourth consecutive board
.
Microelectrophysiology: out of the triple board On October 18, the medical device concept stock microelectrophysiology rose and stopped, recording 3 consecutive boards, reporting 25.
51 yuan / share
.
As of the close, the closing price of the stock was 25.
51 yuan per share
.
On the news, the Fujian Provincial Joint Procurement Center for Pharmaceuticals and Devices recently issued the "Centralized Procurement Document of the Interprovincial Alliance of Cardiac Interventional Electrophysiology Medical Consumables", officially finalizing the centralized procurement plan
for cardiac electrophysiology.
The document mentions that "the minimum bidding rules have been introduced to avoid irrational bidding by enterprises", "the limit price is high, basically the same as the current market price", "the cost pressure of domestic enterprises will be smaller".
.
.
The industry believes that this series of "positives" exceeds market expectations
.
According to Frost & Sullivan's survey data, China's electrophysiology device market has increased from 1.
48 billion yuan in 2015 to 4.
67 billion yuan in 2019, with a compound annual growth rate of 33.
2%.

This market is expected to reach $18.
78 billion by 2024, with a CAGR of 32.
1%
from 2019 to 2024.
With the strengthening of the R&D strength of domestic enterprises and the gentle centralized procurement policy, there is huge
room for domestic upgrading of cardiac interventional electrophysiological consumables.
Microelectrophysiology said that the centralized procurement products have not yet been determined, and two standard catheters are currently being submitted for registration, and may be earlier than expected
.
Now the company's products cover about 700 hospitals
.
According to the data, Microelectrophysiology is an enterprise focusing on the research and development, production and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and treatment and ablation therapy, and is committed to providing globally competitive "integrated solutions for diagnosis and ablation therapy with precise interventional navigation as the core"
.
Shuangcheng Pharmaceutical: won four consecutive boards On October 18, the hepatitis concept stock Shuangcheng Pharmaceutical rose and stopped at 8.
07 yuan / share, reaching 4 consecutive boards
.
As of the close, the stock price rose 9.
98%, closing at 6.
06 yuan
.
It is reported that the stock has risen and stopped 19 times in
the past year.
On the news, the company announced on the evening of September 25 that the company signed an agreement with Meitheal and HKF to grant Meitheal and HKF
the exclusive license of paclitaxel for injection in the United States.
In addition, the company recently replied to investors on the interactive platform that the company has submitted a marketing authorization application
for paclitaxel (albumin-bound) ANDA for injection to the FDA.
Guojin Securities said in a recent research report that the FDA has higher requirements for the purity, impurities, process level and other requirements of drugs than domestic declarations, and it is more difficult for products to be approved in the United States, and the company has successfully obtained more than 60 ANDAs in the United States.

According to the data, the main business of Shuangcheng Pharmaceutical is the research and development, production and sales
of chemically synthesized peptide drugs.
The main products are thymus faxin for injection of Kitai (product name), bivalirudin for injection, levocarnitine for injection, clindamycin hydrochloride for injection, famotidine for injection, somatostatin for injection, and chuanxiongzine
phosphate for injection.
The company has an early
layout in the field of peptide generic drug preparations.
During the 2017 reporting period, the Company underwent a Pre-Approval Inspection (PAI) for Generic Drug (ANDA)
registration applications from the U.
S.
FDA.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.